FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says
This article was originally published in The Pink Sheet Daily
Congress should allow the agency to determine which drug-resistant bacteria sponsors should target in order to earn incentives for antibiotic development, rather than list specific pathogens, CDER Director Janet Woodcock suggested to a House panel March 8. The window to change the GAIN Act appears to be closing, though.
You may also be interested in...
House is expected to vote on the reconciled FDA user fee bill June 20. Negotiators picked Senate GAIN language, including its less prescriptive qualifying pathogen definition.
PhRMA and GPhA exchange unpleasantries over the legislative pay-for; FDA offers a compromise track-and-trace program that would use the industry proposal as a starting point; structure of antibiotic incentives still unresolved.
A conference committee tackles differences between House and Senate FDA user fee and agency reform bills, with an agreement expected before the end of June.